Science and Technology Daily News (Reporter Dai Xiaopei): A randomized controlled clinical trial study of traditional Chinese medicine has recently been published in the Journal of the American Medical Association. The editorial department has also issued rare reviews, editor's notes, and interviews. On November 16th, at a press conference on related achievements held in Beijing, Shen Jianzhong, Deputy Director of the China Biotechnology Development Center, stated that this study is the first randomized controlled clinical trial of traditional Chinese medicine to be published in the four major international medical journals, and is a major breakthrough in evidence-based medicine research of traditional Chinese medicine. This study suggests that Tongxinluo can reduce the risk of death from acute myocardial infarction by 30%. Acute ST segment elevation myocardial infarction (STEMI) has a high mortality rate, and even after receiving reperfusion treatment and optimal medical treatment, patients still face a high risk of hospital mortality and cardiovascular event recurrence. At present, there is still a lack of specific therapeutic drugs worldwide to address this issue. The China Tongxinluo Treatment for Acute Myocardial Infarction Myocardial Protection Study (CTS-AMI) found that adding Tongxinluo capsules to the recommended treatment guidelines can significantly improve the risk of death in STEMI patients. Zhang Boli, an academician of the CAE Member and honorary president of Tianjin University of Traditional Chinese Medicine, said that the research was a major breakthrough in the field of cardiovascular integration of traditional Chinese and western medicine. Gao Runlin, an academician of the CAE Member and professor of Fuwai Hospital of the Chinese Academy of Medical Sciences, said that this study not only added solid evidence-based medical evidence to Tongxinluo, but also provided samples for the integration of traditional Chinese medicine and western medicine and the research of traditional Chinese medicine with modern scientific methods. Based on previous research results, Professor Yang Yuejin from Fuwai Hospital of the Chinese Academy of Medical Sciences led the CTS-AMI research, which is a sub project of the "Research on Intervention of Cardiovascular Event Chains under the Guidance of Vein Theory and Health Theory" project. The study included a total of 3797 STEMI patients from 124 hospitals in China within 24 hours of onset, and conducted a randomized, double-blind, multicenter, placebo-controlled clinical trial. The results showed that Tongxinluo significantly reduced the risk of major adverse cardiovascular and cerebrovascular events (including cardiogenic death, recurrent myocardial infarction, emergency coronary revascularization, and stroke) by 36% and reduced the risk of cardiogenic death by 30%; During the one-year study, Tongxinluo continuously reduced the risk of adverse cardiovascular and cerebrovascular events by 36% and reduced the risk of cardiac death by 27%. Although research has confirmed the clinical efficacy of Tongxinluo in treating STEMI, further research is needed on its active ingredients and mechanism of action. Richard Bach, a professor of cardiology at the Washington Medical School, stated that just like Tu Youyou identified and derived artemisinin from the Chinese herbal medicine Artemisia annua to provide effective drugs for treating malaria, isolating and testing the specific active ingredients of Tongxinluo to provide traditional Chinese medicine for treating STEMI worldwide will be another important breakthrough. (New News Agency)